Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer's
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nicotinic Acetylcholine Receptors Study · Alzheimer's disease research and treatments · Medicinal Plants and Neuroprotection
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Single-cell transcriptomic analysis of Alzheimer's disease10.1038/s41586-019-1195-2 ↗
2. Psychosocial interventions for Alzheimer’s disease cognitive symptoms : a Bayesian network meta-analysis10.1186/s12877-018-0864-6 ↗
3. A review on Alzheimer's disease pathophysiology and its management: an update10.1016/j.pharep.2014.09.004 ↗
4. 2020 Alzheimer's disease facts and figures10.1002/alz.12068 ↗
5. Alzheimer's Association. 2020 Facts and Figures Report
6. World Health Organization. The top 10 causes of death 2014. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed May 13, 2021).
7. World Alzheimer Report 2018 - The state of the art of dementia research: new frontiers
8. Alzheimer’s Statistics
9. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease10.1038/s41582-018-0070-3 ↗
10. The effect of chronic cerebral hypoperfusion on the pathology of Alzheimer's disease: a positron emission tomography study in rats
11. Effect of high fat diet on phenotype, brain transcriptome and lipidome in Alzheimer's model mice10.1038/s41598-017-04412-2 ↗
12. Natural Dietary Supplementation of Anthocyanins via PI3K/Akt/Nrf2/HO-1 Pathways Mitigate Oxidative Stress, Neurodegeneration, and Memory Impairment in a Mouse Model of Alzheimer's Disease10.1007/s12035-017-0798-6 ↗
13. Vitamin d-binding protein-loaded PLGA nanoparticles suppress Alzheimer’s disease-related pathology in 5XFAD mice10.1016/j.nano.2019.02.004 ↗
14. Automatic extraction and assessment of lifestyle exposures for Alzheimer’s disease using natural language processing10.1016/j.ijmedinf.2019.08.003 ↗
15. Nanocarriers for Alzheimer’s disease : research and patent update
16. Alzheimer's disease: targeting the Cholinergic System10.2174/1570159X13666150716165726 ↗
17. Modes and models of forebrain cholinergic neuromodulation of cognition10.1038/npp.2010.104 ↗
18. The effects of the COVID-19 pandemic on people with dementia10.1038/s41582-020-00450-z ↗
19. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimer's
20. Awareness of the COVID-19 outbreak and resultant depressive tendencies in patients with severe Alzheimer's disease10.3233/JAD-200832 ↗
21. COVID-19: review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications10.3233/JAD-200831 ↗
22. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia10.3389/fnagi.2020.588872 ↗
23. Alzheimer's and parkinson's diseases predict different COVID-19 outcomes: a UK biobank study10.3390/geriatrics6010010 ↗
24. COVID-19 and Alzheimer's disease: how one crisis worsens the other10.1186/s40035-021-00237-2 ↗
25. Nanotargeting of Drugs for Delaying Dementia : relevance of Covid-19 Impact on Dementia
26. Advances in developing novel therapeutic strategies for Alzheimer's disease10.1186/s13024-018-0299-8 ↗
27. A molecular approach in drug development for Alzheimer's disease10.1016/j.biopha.2018.06.147 ↗
28. Framework of treating Alzheimer's dementia10.1177/2096595820902580 ↗
29. Cholinergic transmission in C. elegans: functions, diversity, and maturation of ACh-activated ion channels
30. Use of memantine for the treatment of dementia10.1586/ern.11.132 ↗
31. Progress and perspectives on targeting nanoparticles for brain drug delivery10.1016/j.apsb.2016.05.013 ↗
32. Examining the uptake of central nervous system drugs and candidates across the blood-brain barrier10.1124/jpet.116.232447 ↗
33. Pharmacokinetics of memantine in rats and mice
34. Memantine transport across the mouse blood-brain barrier is mediated by a cationic influx H+ antiporter10.1021/mp400316e ↗
35. Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer's disease10.1038/s41598-019-46032-y ↗
36. Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations10.3109/10717544.2015.1089956 ↗
37. Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: enhanced Brain Distribution and Pharmacodynamics10.1016/j.xphs.2017.08.024 ↗
38. Anti-Dementia Drugs and Hepatotoxicity–Report of Two Cases10.1016/j.ijge.2018.02.008 ↗
39. Memantine-induced hepatitis with cholestasis in a very elderly patient10.7326/0003-4819-148-8-200804150-00023 ↗
40. Memantine-associated hyperkalaemia in a patient with Alzheimer's disease10.1111/psyg.12022 ↗
41. Memantine-associated renal impairment in a patient with Alzheimer's disease10.1111/pcn.12020 ↗
42. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo10.1016/j.ijpharm.2006.11.013 ↗
43. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies10.1016/j.apsb.2021.02.012 ↗
44. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting10.3390/pharmaceutics10010034 ↗
45. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs10.1016/j.jconrel.2018.05.011 ↗
46. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics10.1016/j.ejpb.2018.05.009 ↗
47. Nose-to-Brain Delivery : evaluation of Polymeric Nanoparticles on Olfactory Ensheathing Cells Uptake10.1002/jps.23836 ↗
48. Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease10.1016/j.lfs.2018.06.032 ↗
49. Demonstration of an olfactory bulb-brain translocation pathway for ZnO nanoparticles in rodent cells in vitro and in vivo10.1007/s12031-012-9756-y ↗
50. Intranasal delivery of nanoparticle encapsulated taren fl urbil : a potential brain targeting strategy for Alzheimer’s disease10.1016/j.ejps.2016.05.012 ↗
51. Intranasal Cerebrolysin Attenuates Learning and Memory Impairments in d-galactose-Induced Senescence in Mice10.1016/j.exger.2016.11.011 ↗
52. Intranasal Delivery of Collagen-Loaded Neprilysin Clears Beta-Amyloid Plaques in a Transgenic Alzheimer Mouse Model10.3389/fnagi.2021.649646 ↗
53. Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting
54. Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders10.1016/j.jddst.2017.09.022 ↗
55. In situ nasal gel drug delivery: a novel approach for brain targeting through the mucosal membrane
56. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer’s disease management: preparation and detection in rat brain10.3109/03639045.2015.1062897 ↗
57. Intranasal nanoemulsions for direct nose-to-brain delivery of actives for cns disorders10.3390/pharmaceutics12121230 ↗
58. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease10.1016/j.ejpb.2019.12.014 ↗
59. Liposomes functionalized to overcome the blood – brain barrier and to target amyloid- β peptide : the chemical design affects the permeability across an in vitro model
60. Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer’s disease
61. Nose to Brain Delivery of Galantamine Loaded Nanoparticles: in-vivo Pharmacodynamic and Biochemical Study in Mice10.2174/1567201815666181004094707 ↗
62. Phytochemical-loaded mesoporous silica nanoparticles for nose-to -brain olfactory drug delivery10.1016/j.ijpharm.2016.09.042 ↗
63. Pharmacological, toxicological and neuronal localization assessment of galantamine /chitosan complex nanoparticles in rats : future potential contribution in Alzheimer’s disease management10.3109/10717544.2016.1153748 ↗
64. Intranasal galantamine /chitosan complex nanoparticles elicit neuroprotection potentials in rat brains via antioxidant effect
65. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen : implications for the treatment of Alzheimer’s disease10.1111/jphp.12836 ↗
66. Galantamine nanoparticles outperform oral galantamine in an Alzheimer's rat model: pharmacokinetics and pharmacodynamics10.2217/nnm-2021-0051 ↗
67. Solid lipid nanoparticles for nose to brain delivery of donepezil: formulation, optimization by Box–Behnken design, in vitro and in vivo evaluation. Artif Cells
68. Osthole-Loaded Nanoemulsion Enhances Brain Target in the Treatment of Alzheimer's Disease via Intranasal Administration
69. Surface modified nano-lipid drug conjugates of positive allosteric modulators of M1 muscarinic acetylcholine receptor for the treatment of Alzheimer's disease10.1016/j.mehy.2017.01.026 ↗
70. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease10.1186/s13024-020-00391-7 ↗
71. Alzheimer's Disorder: epigenetic Connection and Associated Risk Factors10.2174/1570159X18666200128125641 ↗
72. PM20D1 is a quantitative trait locus associated with Alzheimer's disease10.1038/s41591-018-0013-y ↗
73. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease10.1038/s41593-018-0154-9 ↗
74. Mitochondrial ubiquitin ligase alleviates Alzheimer's disease pathology via blocking the toxic amyloid-β oligomer generation10.1038/s42003-021-01720-2 ↗
75. Toward a holistic model of Alzheimer's
76. Senescent glia spell trouble in Alzheimer's disease10.1038/s41593-019-0395-2 ↗
77. Update on Alzheimer's Disease Therapy and Prevention Strategies10.1146/annurev-med-042915-103753 ↗
78. The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression10.1038/s41598-020-80164-w ↗
79. Amyloid beta: structure, biology and structure-based therapeutic development10.1038/aps.2017.28 ↗
80. Label-free vibrational imaging of different Aβ plaque types in Alzheimer's disease reveals sequential events in plaque development10.1186/s40478-020-01091-5 ↗
81. Soluble amyloid-beta aggregates from human Alzheimer's disease brains10.1038/srep38187 ↗
82. Alterations in tau protein level and phosphorylation state in the brain of the autistic-like rats induced by prenatal exposure to valproic acid10.3390/ijms22063209 ↗
83. Molecular pathogenesis of alzheimer's disease: an update10.1159/000464422 ↗
84. The role of protein misfolding and tau oligomers (TauOs) in Alzheimer's disease (AD)10.3390/ijms20194661 ↗
85. The Glymphatic System in Central Nervous System Health and Disease: past, Present, and Future10.1146/annurev-pathol-051217-111018 ↗
86. Perivascular spaces and brain waste clearance systems: relevance for neurodegenerative and cerebrovascular pathology10.1007/s00234-021-02718-7 ↗
87. Glymphatic system impairment in Alzheimer’s disease and idiopathic normal pressure hydrocephalus10.1016/j.molmed.2019.11.008 ↗
88. In vivo assessment of cerebrospinal fluid efflux to nasal mucosa in humans10.1038/s41598-020-72031-5 ↗
89. Peripheral clearance of brain-derived Aβ in Alzheimer's disease: pathophysiology and therapeutic perspectives10.1186/s40035-020-00195-1 ↗
90. Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer's disease mice10.1016/j.actbio.2020.03.029 ↗
91. Neuronal mitochondria-targeted therapy for Alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems10.1080/10717544.2020.1745328 ↗
92. Zinc ion rapidly induces toxic, off-pathway amyloid- β oligomers distinct from amyloid- β derived diffusible ligands in Alzheimer’s disease
93. Associative interactions among zinc, apolipoprotein E, and amyloid-β in the amyloid pathology
94. Neurotoxicity of Zinc10.1007/978-3-319-60189-2_15 ↗
95. Brazilin inhibits the Zn 2 + -mediated aggregation of amyloid β -protein and alleviates cytotoxicity10.1016/j.jinorgbio.2017.09.015 ↗
96. Therapeutic B-cell depletion reverses progression of Alzheimer's disease
97. A Multilevel View of the Development of Alzheimer's Disease10.1016/j.neuroscience.2020.11.015 ↗
98. Alzheimer's disease drug development pipeline: 2020. Alzheimer's
99. Current and emerging avenues for Alzheimer's disease drug targets10.1111/joim.12959 ↗
100. Therapeutic nanoparticles and their targeted delivery applications10.3390/molecules25092193 ↗